|
Alka-372-001: First-in-human, phase I study of entrectinib – an oral pan-trk, ROS1, and ALK inhibitor – in patients with advanced solid tumors with relevant molecular alterations. |
| |
|
Travel, Accommodations, Expenses - ignyta |
| |
|
No Relationships to Disclose |
| |
|
Travel, Accommodations, Expenses - Amgen |
| |
|
No Relationships to Disclose |
| |
|
No Relationships to Disclose |
| |
|
No Relationships to Disclose |
| |
|
No Relationships to Disclose |
| |
|
No Relationships to Disclose |
| |
|
No Relationships to Disclose |
| |
|
No Relationships to Disclose |
| |
|
No Relationships to Disclose |
| |
|
Consulting or Advisory Role - Amgen; Bayer; Merck Serono |
Speakers' Bureau - Amgen; Bayer; Merck Serono; Roche Pharma AG |
| |
|
Employment - Nerviano Medical Sciences |
Leadership - Nerviano Medical Sciences |
| |
|
Employment - Nerviano Medical Sciences |
Leadership - Nerviano Medical Sciences |
| |
|
Employment - Nerviano Medical Sciences |
| |
|
Employment - Nerviano Medical Sciences |
Leadership - Nerviano Medical Sciences |
| |
|
|
Stock and Other Ownership Interests - Ignyta |
Travel, Accommodations, Expenses - Ignyta |
| |
|
|
Travel, Accommodations, Expenses - Ignyta |
| |
|
|
|
Stock and Other Ownership Interests - ignyta |
|
Consulting or Advisory Role - Ignyta |
Speakers' Bureau - ignyta |
Travel, Accommodations, Expenses - ignyta |
| |
|
Stock and Other Ownership Interests - Ignyta |
|
Consulting or Advisory Role - Amgen; Bayer; Ignyta; Roche/Genentech; Sanofi |
Speakers' Bureau - Amgen; Bayer |
Research Funding - Bayer (Inst) |
Patents, Royalties, Other Intellectual Property - Amgen |
Travel, Accommodations, Expenses - Amgen; Bayer; Roche |